U.S. General Anesthesia Drugs Market To Reach $2.03 Billion By 2030

U.S. General Anesthesia Drugs Market Growth & Trends

The U.S. general anesthesia drugs market size is projected to reach USD 2.03 billion by 2030, and is anticipated to grow at a CAGR of 2.8% from 2024 to 2030, according to Grand View Research, Inc. The rising number of surgical procedures primarily drives this growth. The American Society of Anesthesiologists (ASA) highlights a consistent increase in surgeries, attributed to an aging population, the growing prevalence of chronic diseases, and advancements in surgical techniques. The CDC reported in February 2024 that approximately 129 million Americans have at least one major chronic disease, such as cancer, heart disease, diabetes, and hypertension. This high prevalence of chronic conditions necessitates numerous cardiovascular and other surgeries, which in turn drives the demand for effective general anesthesia drugs.

Advancements in anesthesia technology are another critical driver. Innovations such as ultra-short-acting anesthetics, like remifentanil, offer improved control over anesthesia depth and faster recovery times, enhancing patient outcomes and driving market growth. Additionally, the development of advanced delivery systems and monitoring technologies, including automated anesthesia delivery systems, has revolutionized anesthesia practices by improving precision and safety.

Regulatory developments also play a significant role. The FDA's expedited approval pathways for breakthrough therapies facilitate quicker access to new and effective anesthetics. For instance, the recent approval of ZYNRELEFTM, a novel extended-release anesthetic, illustrates how regulatory advancements support the introduction of innovative products.

 Request a free sample copy or view report summary: U.S. General Anesthesia Drugs Market Report

U.S. General Anesthesia Drugs Market Report Highlights

• Based on drug, the propofol segment dominated the market with a substantial revenue share of 25.4% in 2023 and is also expected to grow at the fastest CAGR of 3.4% during the forecast period, driven by its widespread use as a preferred agent for induction and maintenance of general anesthesia.

• Based on route of administration, the intravenous segment held the largest revenue share of 63.1% in 2023 and is also expected to grow at the fastest CAGR of 3.0% during the forecast period

• Based on application, the knee and hip replacements segment dominated the market, capturing a substantial revenue share.

• Based on end use, the hospitals segment dominated the market, capturing a substantial revenue share of 67.2% in 2023. Hospitals are the primary settings for major surgeries and complex medical procedures that require general anesthesia.

U.S. General Anesthesia Drugs Market Segmentation

Grand View Research has segmented the U.S. general anesthesia drugs market report based on drug, route of administration, application, end-use and region:

U.S. General Anesthesia Drug Outlook (Revenue, USD Million, 2018 - 2030)

• Sevoflurane

• Propofol

• Dexmedetomidine

• Remifentanil

• Desflurane

• Midazolam

• Others - (Sufentanil, Fentanyl, Ketamine, Isoflurane, Thiopental, etc.)

U.S. General Anesthesia Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)

• Intravenous

• Inhaled

U.S. General Anesthesia End-use Outlook (Revenue, USD Million, 2018 - 2030)

• Hospitals

• Ambulatory Surgical Centers

• Others 

U.S. General Anesthesia Application Outlook (Revenue, USD Million, 2018 - 2030)

• Heart Surgeries

• Cancer

• General Surgery

• Knee and hip replacements

• Others

List of Key Players in theU.S. General Anesthesia Drugs Market

• Baxter International Inc.

• AstraZeneca

• AbbVie Inc.

• B. Braun Melsungen AG

• Fresenius SE & Co. KgaA

• Pfizer

• Hospira Inc.

• Aspen Pharmacare Holdings Limited

• Hikama Pharmaceuticals plc

• Abbott Laboratories